WEBULL
News
MGTX
7.76
+5.29%
0.39
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at MGTX last week (0302-0306)?
Weekly Report · 1d ago
Controversial Prasad leaving FDA, NYT reports
TipRanks · 2d ago
Weekly Report: what happened at MGTX last week (0223-0227)?
Weekly Report · 03/02 09:14
Weekly Report: what happened at MGTX last week (0216-0220)?
Weekly Report · 02/23 09:14
Weekly Report: what happened at MGTX last week (0209-0213)?
Weekly Report · 02/16 09:14
Weekly Report: what happened at MGTX last week (0202-0206)?
Weekly Report · 02/09 09:14
MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy
TipRanks · 02/03 13:16
MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy
Reuters · 02/03 13:03
MeiraGTx Holdings plc schließt exklusive Lizenzvereinbarung mit ZipBio für Gentherapie bei geografischer Atrophie
Reuters · 02/03 13:03
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
PR Newswire · 02/03 13:00
Weekly Report: what happened at MGTX last week (0126-0130)?
Weekly Report · 02/02 09:14
Weekly Report: what happened at MGTX last week (0119-0123)?
Weekly Report · 01/26 09:14
Weekly Report: what happened at MGTX last week (0112-0116)?
Weekly Report · 01/19 09:15
Weekly Report: what happened at MGTX last week (0105-0109)?
Weekly Report · 01/12 09:15
MeiraGTx price target lowered to $14 from $15 at BofA
TipRanks · 01/06 15:25
Meiragtx Holdings (MGTX) Receives a Buy from Bank of America Securities
TipRanks · 01/06 12:47
Weekly Report: what happened at MGTX last week (1229-0102)?
Weekly Report · 01/05 09:14
MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors
Seeking Alpha · 01/02 13:42
MeiraGTx Announces Share Repurchase and Investor Lock-Up
TipRanks · 01/02 13:26
More
Webull provides a variety of real-time MGTX stock news. You can receive the latest news about Meiragtx Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.